On December 2, 2020 Apotex Corp. reported that its board of directors has appointed Peter Hardwick as President & Chief Executive Officer of Apotex Corp., effective immediately (Press release, Apotex, DEC 2, 2020, View Source;chief-executive-officer-301183018.html [SID1234572100]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This announcement serves to formalize Peter’s leadership role, and no other changes to operations or structure are currently being planned. Peter, who has been with Apotex Inc. for 14 years, has served in an interim leadership role with Apotex Corp. since 2019, helping to navigate the business through unprecedented challenges created by the pandemic.

"Peter’s track record as a commercial executive in the pharmaceutical industry has been demonstrated time and again," said Jeff Watson, Global President & Chief Executive Officer, Apotex Inc. "The US market continues to be a growth engine for Apotex and under Peter’s leadership, I have every confidence this will be further accelerated."